{'52WeekChange': 2.4279602,
 'SandP52WeekChange': 0.0644362,
 'address1': '499 Illinois Street',
 'address2': 'Suite 500',
 'algorithm': None,
 'annualHoldingsTurnover': None,
 'annualReportExpenseRatio': None,
 'ask': 49,
 'askSize': 1400,
 'averageDailyVolume10Day': 876875,
 'averageVolume': 1531534,
 'averageVolume10days': 876875,
 'beta': None,
 'beta3Year': None,
 'bid': 46.5,
 'bidSize': 2900,
 'bookValue': -23.942,
 'category': None,
 'circulatingSupply': None,
 'city': 'San Francisco',
 'companyOfficers': [],
 'country': 'United States',
 'currency': 'USD',
 'dateShortInterest': 1593475200,
 'dayHigh': 48.47,
 'dayLow': 46.31,
 'dividendRate': None,
 'dividendYield': None,
 'earningsQuarterlyGrowth': None,
 'enterpriseToEbitda': -25.272,
 'enterpriseToRevenue': 525.078,
 'enterpriseValue': 5328486912,
 'exDividendDate': None,
 'exchange': 'NMS',
 'exchangeTimezoneName': 'America/New_York',
 'exchangeTimezoneShortName': 'EDT',
 'expireDate': None,
 'fiftyDayAverage': 42.614857,
 'fiftyTwoWeekHigh': 75,
 'fiftyTwoWeekLow': 11.65,
 'fiveYearAverageReturn': None,
 'fiveYearAvgDividendYield': None,
 'floatShares': 54794874,
 'forwardEps': -1.89,
 'forwardPE': -25.428572,
 'fromCurrency': None,
 'fullTimeEmployees': 237,
 'fundFamily': None,
 'fundInceptionDate': None,
 'gmtOffSetMilliseconds': '-14400000',
 'heldPercentInsiders': 0.14543,
 'heldPercentInstitutions': 0.63778996,
 'industry': 'Biotechnology',
 'isEsgPopulated': False,
 'lastCapGain': None,
 'lastDividendValue': None,
 'lastFiscalYearEnd': 1577750400,
 'lastMarket': None,
 'lastSplitDate': None,
 'lastSplitFactor': None,
 'legalType': None,
 'logo_url': 'https://logo.clearbit.com/vir.bio',
 'longBusinessSummary': 'Vir Biotechnology, Inc., a clinical-stage immunology '
                        'company, develops therapeutic products to treat and '
                        'prevent serious infectious diseases. It develops '
                        'VIR-2218 and VIR-3434 for the treatment of hepatitis '
                        'B virus; VIR-2482 for the prevention of influenza A '
                        'virus; VIR-1111 for the prevention of human '
                        'immunodeficiency virus; and VIR-2020 for the '
                        'prevention of tuberculosis. The company has grant '
                        'agreements with Bill & Melinda Gates Foundation and '
                        'National Institutes of Health; an option and license '
                        'agreement with Brii Biosciences Limited and Brii '
                        'Biosciences Offshore Limited; a collaboration and '
                        'license agreement with Alnylam Pharmaceuticals, Inc.; '
                        'a collaboration, license, and option agreement with '
                        'Visterra, Inc.; license agreements with The '
                        'Rockefeller University and MedImmune, Inc.; a '
                        'collaboration with WuXi Biologics; and a '
                        'collaborative research agreement with Generation '
                        'Bio., as well as GlaxoSmithKline Intellectual '
                        'Property Development Limited, GlaxoSmithKline '
                        'Biologicals SA., and Alnylam Pharmaceuticals, Inc. It '
                        'also has a manufacturing agreement with Samsung '
                        'Biologics Co.,Ltd. for the manufacture of SARS-COV-2 '
                        'antibodies for potential COVID-19 treatment. Vir '
                        'Biotechnology, Inc. was founded in 2016 and is '
                        'headquartered in San Francisco, California.',
 'longName': 'Vir Biotechnology, Inc.',
 'market': 'us_market',
 'marketCap': 6071323648,
 'maxAge': 1,
 'maxSupply': None,
 'messageBoardId': 'finmb_419881198',
 'morningStarOverallRating': None,
 'morningStarRiskRating': None,
 'mostRecentQuarter': 1585612800,
 'navPrice': None,
 'netIncomeToCommon': -223252992,
 'nextFiscalYearEnd': 1640908800,
 'open': 47.27,
 'openInterest': None,
 'payoutRatio': 0,
 'pegRatio': None,
 'phone': '415-906-4324',
 'previousClose': 49.09,
 'priceHint': 2,
 'priceToBook': None,
 'priceToSalesTrailing12Months': 598.27783,
 'profitMargins': 0,
 'quoteType': 'EQUITY',
 'regularMarketDayHigh': 48.47,
 'regularMarketDayLow': 46.31,
 'regularMarketOpen': 47.27,
 'regularMarketPreviousClose': 49.09,
 'regularMarketPrice': 47.27,
 'regularMarketVolume': 621942,
 'revenueQuarterlyGrowth': None,
 'sector': 'Healthcare',
 'sharesOutstanding': 126328000,
 'sharesPercentSharesOut': 0.036,
 'sharesShort': 4256773,
 'sharesShortPreviousMonthDate': 1590710400,
 'sharesShortPriorMonth': 2047638,
 'shortName': 'Vir Biotechnology, Inc.',
 'shortPercentOfFloat': 0.0773,
 'shortRatio': 2.26,
 'startDate': None,
 'state': 'CA',
 'strikePrice': None,
 'symbol': 'VIR',
 'threeYearAverageReturn': None,
 'toCurrency': None,
 'totalAssets': None,
 'tradeable': False,
 'trailingAnnualDividendRate': None,
 'trailingAnnualDividendYield': None,
 'trailingEps': -14.642,
 'twoHundredDayAverage': 32.759243,
 'volume': 621942,
 'volume24Hr': None,
 'volumeAllCurrencies': None,
 'website': 'http://www.vir.bio',
 'yield': None,
 'ytdReturn': None,
 'zip': '94158'}